GRFS (Grifols) YoY EBITDA Growth: -4.77% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GRFS Grifols SA GRFS
82 GF Score
Price $7.94
GF Value $8.32
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Grifols YoY EBITDA Growth?

Grifols GRFS -1.85% 82 YoY EBITDA Growth is -4.77% as of Jun. 2026. GuruFocus rates GRFS with a GF Score™ of 82/100 and a GF Value™ of $8.32 (Fairly Valued). The stock has 7 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Grifols's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -4.77%.

Grifols's EBITDA per Share for the three months ended in Jun. 2026 was $0.74.

Grifols YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Grifols's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols YoY EBITDA Growth Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -38.02 18.85 0.75 21.93 23.37

Grifols Quarterly Data
Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.81 13.38 15.67 -2.12 -4.77
GRFS
82GF Score
Grifols SA GRFS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Grifols's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(2.819-2.285)/ | 2.285 |
=23.37 %

Grifols's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.738-0.775)/ | 0.775 |
=-4.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -4.77% mean?
Grifols (GRFS) has a YoY EBITDA Growth of -4.77% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Grifols and its competitors.
Is Grifols' YoY EBITDA Growth too high?
Grifols' current YoY EBITDA Growth is -4.77%. Overall, Grifols has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Grifols' YoY EBITDA Growth compare to LLY and JNJ?
Grifols' YoY EBITDA Growth of -4.77% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Grifols and its competitors. Grifols's current YoY EBITDA Growth is -4.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Fairly Valued. The stock's GF Value™ is $8.32, compared to a current price of $7.94 — trading 4.6% below its estimated fair value. The current YoY EBITDA Growth is -4.77%. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Grifols (GRFS), the current YoY EBITDA Growth is -4.77% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.94 is trading 4.6% below its estimated GF Value™ of $8.32. GuruFocus considers Grifols to be Fairly Valued.

Key valuation signals for GRFS:

  • YoY EBITDA Growth: -4.77%
  • GF Value™: $8.32 vs. price of $7.94 (4.6% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score

Get the complete analysis for GRFS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.94
Price
$8.32
GF Value